Vyome (HIND) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vyome (HIND) has outperformed Niki BioSolutions (NIKI) over the past year, losing 65.4% versus a loss of 82.1%. Over five years, NIKI leads with a -98.3% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($14.2 million vs $12.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | NIKI |
|---|---|---|
| Share price | $2.03 | $4.00 |
| Market cap | $14.25M | $12.47M |
| 1-day change | 0.00% | -7.41% |
| YTD return | -40.99% | -59.25% |
| 1-year return | -65.42% | -82.07% |
| 5-year return | -100.00% | -98.33% |
| P/E ratio (TTM) | 1.14 | — |
| EPS (TTM) | $1.78 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.56 | $24.00 |
| 52-week low | $1.75 | $4.00 |
| Distance from 52-week high | -69.05% | -83.33% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +334.98% | — |
| Average volume | 13.32K | 157.52K |
| Shares outstanding | 7.02M | 2.94M |
| Employees | 9 | 1 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HIND has outperformed NIKI by 16.7 percentage points over the past year.
- The two companies sit in different sectors: Vyome in Health Care and Niki BioSolutions in Industrials.
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
HIND vs NIKI FAQ
Which is bigger, Vyome or Niki BioSolutions?
Vyome (HIND) is larger, with a market capitalization of $14.25M compared with $12.47M for Niki BioSolutions (NIKI).
Which stock has performed better over the past year, HIND or NIKI?
HIND returned -65.42% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are Vyome and Niki BioSolutions in the same industry?
No. Vyome is in the Health Care sector, while Niki BioSolutions is in Industrials.